Clinical Pharmacology : Advances and Applications最新文献

{"title":"Diagnostic Significance of Paraneoplastic Neuronal Antibodies in Japanese Adults with Autoimmune Encephalitis: A Case Series Study in an Adult Epilepsy Clinic.","authors":"Masako Kinoshita, Kozue Takada, Hiroya Ohara, Toshi Sai, Ajay Elangovan, Harysh Winster Suresh Babu, Balachandar Vellingiri, Takeshi Satow","doi":"10.2147/CPAA.S514609","DOIUrl":"10.2147/CPAA.S514609","url":null,"abstract":"<p><strong>Purpose: </strong>Recently, the role of autoimmune mechanisms in epileptogenesis and intractability has attracted attention. The clinical features of autoimmune encephalitis (AE) vary; thus, diagnosis can be difficult and often delayed. Paraneoplastic neurological syndromes are usually associated with malignant cancers; however, paraneoplastic antibodies (PAs) can be present in the absence of overt cancers. In this single-center, retrospective study, we evaluated the diagnostic significance of PAs in adult Japanese patients with AE.</p><p><strong>Patients and methods: </strong>We retrospectively analyzed the medical records of all patients who visited our epilepsy clinic and underwent a thorough diagnostic evaluation for AE between April 2021 and October 2022. Patients who met the criteria for AE and presented to our epilepsy clinic with new-onset seizures or acute or subacute seizure aggravation were included. Data from the PA panel, including anti-amphiphysin (AMPH), CV2, paraneoplastic Ma antigen 2 (PNMA2), Ri, Yo, Hu, recoverin, SRY-related HMG-box gene 1 (SOX1), titin, zic4, glutamate decarboxylase 65 (GAD65), and Tr/DNER antibodies, were evaluated.</p><p><strong>Results: </strong>Of 32 patients who were investigated, 6 (19.0%; 2 males, age: 38.0 ± 18.0 years) were positive for PAs (anti-AMPH: 1, PNMA2: 1, Yo: 1, recoverin: 2, SOX1: 1). No patients had malignant tumors. Serum anti-SS-A/Ro antibodies were detected in one patient, and the cerebrospinal fluid showed a slightly elevated protein level. Intravenous high-dose methylprednisolone was administered to four patients and was effective in three.</p><p><strong>Conclusion: </strong>Approximately one-fifth of AE cases were attributable to PAs, although there were no signs of malignant tumors, in adult epilepsy clinics in Japan.</p>","PeriodicalId":10406,"journal":{"name":"Clinical Pharmacology : Advances and Applications","volume":"17 ","pages":"155-166"},"PeriodicalIF":3.1,"publicationDate":"2025-06-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12227317/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144574927","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Effect of Drug-Drug Interactions on the Pharmacokinetics of Isavuconazole: A Comprehensive Review.","authors":"Yanlei Sang, Qiang Xu, Anna Gao, Qingwei Zhao","doi":"10.2147/CPAA.S526869","DOIUrl":"10.2147/CPAA.S526869","url":null,"abstract":"<p><strong>Purpose: </strong>Isavuconazole is an azole antifungal drug, which is used for invasive aspergillosis and mucormycosis. The objective of this study was to comprehensive review the impact of drug-drug interactions (DDIs) on isavuconazole pharmacokinetics by categorizing concomitant medications as enzyme inducers (eg, rifampicin), inhibitors (eg, ritonavir), or neutral agents. Additionally, we aimed to evaluate whether the duration of combination therapy modulates the magnitude of DDIs and provide references for clinical medication.</p><p><strong>Methods: </strong>The literature concerning the interactions of isavuconazole was systematically retrieved from three retrieval platforms, PUBMED, EMBASE, and the Cochrane Library, using the search terms: \"isavuconazole\" or \"isavuconazonium\" or \"Cresemba\" and \"interact*\", or \"cotreatment\", or \"coadministration\", or \"combination\", or \"concomitant\". A total of 1051 articles were retrieved and then conduct screening according to the inclusion and exclusion criteria.</p><p><strong>Results: </strong>Eleven studies involving 23 drugs were included in this study. Rifampicin, flucloxacillin, and phenobarbital decreased the exposure of isavuconazole. Ketoconazole and ritonavir significantly increased the exposure of isavuconazole. Esomeprazole, had no significant effects on the exposure of isavuconazole. Although midazolam, estradiol/norethisterone, atorvastatin, digoxin, metformin, methotrexate, bupropion, repaglinide, dextromethorphan, caffeine, methadone, warfarin, cyclosporine, tacrolimus, sirolimus, prednisone, and mycophenolate mofetil had also no significant effect on isavuconazole pharmacokinetics, a single-dose administration cannot induce or inhibit metabolic enzymes stably, and we consider the results to be unreliable. Therefore, these drugs still need to be used with caution.</p><p><strong>Conclusion: </strong>This review demonstrates that drug interactions of isavuconazole are predominantly mediated by the CYP3A4/P-glycoprotein pathway: strong inducers (eg, rifampicin) reduce its exposure, while strong inhibitors (eg, ketoconazole) increase exposure. Single-dose interaction studies are unreliable due to insufficient time for enzyme regulation, highlighting the need to consider the duration of combination therapy. Clinical recommendations: avoid coadministration with strong inducers/inhibitors and implement therapeutic drug monitoring (TDM) for patients on long-term combination therapy to optimize dosing regimens.</p>","PeriodicalId":10406,"journal":{"name":"Clinical Pharmacology : Advances and Applications","volume":"17 ","pages":"143-153"},"PeriodicalIF":3.1,"publicationDate":"2025-06-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12182230/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144474140","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Triphenylphosphine-Based Mitochondrial Targeting Nanocarriers: Advancing Cancer Therapy.","authors":"Mohd Shoab Ali, B H Jaswanth Gowda, Rahul Shukla, Prashant Kesharwani","doi":"10.2147/CPAA.S526895","DOIUrl":"10.2147/CPAA.S526895","url":null,"abstract":"<p><p>Numerous chemotherapeutic drugs are commercially available for cancer treatment; however, their efficacy is often compromised by diminishing therapeutic effectiveness and unpredictable adverse effects. The lack of specific targeting limits their optimal therapeutic potential. Mitochondria are the primary sites of cellular energy production and play a critical role in cell survival and death. Furthermore, numerous studies have found an apparent association between mitochondrial metabolism and carcinogenesis and progression. Therefore, significant attention has been directed toward nanocarriers specifically designed for mitochondrial delivery, aiming to enhance the precision of chemotherapeutic agent transport to these critical organelles. Among these, triphenylphosphonium has emerged as a prominent mitochondrial targeting agent due to its superior targeting capabilities. This approach not only reduces the required drug dosage but also minimizes adverse effects on healthy tissues. This review provides a concise analysis of nanotechnology's contributions to cancer therapy, emphasizing its potential for targeting at both cellular and sub-cellular levels. Additionally, it delves into mitochondrial targeting, with a particular focus on nanocarriers engineered for efficient mitochondrial drug delivery. Moreover, it focuses on strategies employed by researchers to introduce TPP in nanocarrier systems for mitochondrial delivery and concludes by addressing challenges associated with TPP including hemolytic activity and how researchers mitigate this issue.</p>","PeriodicalId":10406,"journal":{"name":"Clinical Pharmacology : Advances and Applications","volume":"17 ","pages":"119-141"},"PeriodicalIF":3.1,"publicationDate":"2025-06-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12168994/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144309649","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Novel Therapies in Primary Central Nervous System Lymphoma.","authors":"Michel Wakim, Mariana Mezher, Ariel Perez-Perez, Arun Maharaj, Yazmin Odia, Manmeet S Ahluwalia, Yuliya Linhares","doi":"10.2147/CPAA.S501065","DOIUrl":"10.2147/CPAA.S501065","url":null,"abstract":"<p><p>Primary central nervous system lymphoma (PCNSL) is a rare, aggressive, extranodal lymphoma exclusively located in the central nervous system. High-dose methotrexate (HD-MTX)-based chemotherapy combination regimens are now the standard of care for the upfront treatment of PCNSL and are used in a salvage setting but are toxic and cumbersome to administer because of the need for inpatient supportive care. While the incidence of PCNSL is increasing in the aging population, a significant proportion of patients are unable to follow HD-MTX protocols owing to performance status and organ dysfunction. Consolidative autologous stem cell transplant or whole-brain radiation therapy improves progression-free survival at the cost of short- and long-term toxicities. Induction of low toxicity and consolidative and salvage therapeutic options are lacking. Due to its unique biology, PCNSL presents an exciting opportunity for the development of novel therapies with improved efficacy and toxicity. In this review, we focus on the biology of PCNSL and novel chemotherapeutics, including targeted and immunotherapeutic agents as well as cellular therapies. Expert Opinion summary: Given the lack of low-toxicity standard treatments for PCNSL, the outcomes for aging PCNSL patients remain suboptimal. Current research has focused on introducing targeted immunotherapies into the induction, salvage, and consolidation treatments of PCNSL.</p>","PeriodicalId":10406,"journal":{"name":"Clinical Pharmacology : Advances and Applications","volume":"17 ","pages":"97-117"},"PeriodicalIF":3.1,"publicationDate":"2025-05-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12126982/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144198415","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Predictive Analysis of Non-Cardiac Drug-Induced QTc Interval Prolongation: A Cross-Sectional Study.","authors":"Nataleen A Albekairy, Reema Abdullah Aldawsari, Sarah Alanazi, Nora Almutairi, Nora AlSayari, Salem Abu Al-Burak, Mona Abubakr Bawazeer, Lama Alfehaid, Mohammad S Shawaqfeh","doi":"10.2147/CPAA.S509476","DOIUrl":"10.2147/CPAA.S509476","url":null,"abstract":"<p><strong>Purpose: </strong>This study aimed to assess the real-world impacts of non-cardiac drug-induced QTc interval prolongation and identify associated risk factors in acute care settings.</p><p><strong>Patients and methods: </strong>A cross-sectional study reviewed medical charts of 7,778 patients admitted to tertiary teaching hospitals from January 2016 to December 2022. Patients on CredibleMeds-listed QTc-prolonging non-cardiac drugs were identified, excluding those with congenital long QTc syndrome or on QTc-prolonging cardiac medications. Data collection involved reviewing medication charts and recording demographic and clinical data, including comorbidities and laboratory values. A logistic regression analysis was performed to address confounders, and known risk factors, calculating Odds Ratios (OR) and 95% confidence intervals (CI). Statistical analysis used SPSS Version 21.0, with p < 0.05 indicating significance.</p><p><strong>Results: </strong>Out of 7,778 screened patients, 151 met the inclusion criteria. Among these, 75.5% demonstrated prolonged QTc values. The study identified 42 distinct medications associated with QT interval prolongation, categorized into six therapeutic groups. Proton pump inhibitors (PPIs) were the most common cause of non-cardiac drug-induced QTc interval prolongation, with esomeprazole representing 46.5% of the cases. Antimicrobial medications followed, with azithromycin at 9.6% and piperacillin-tazobactam at 6.1%. The multivariate analysis revealed that heart failure was significantly associated with QTc prolongation odd ratio (OR) 4.98 with 95% confidence interval CI [1.58 to 17.35], while other factors such as age, BMI, and certain comorbidities did not show a statistically significant impact.</p><p><strong>Conclusion: </strong>The findings highlight the significant risk associated with the in-hospital administration of QTc-prolonging non-cardiac medications, particularly among patients with heart failure. Future research should aim to include a larger patient population and employ comprehensive data collection methods across multiple centers to enhance the robustness and generalizability of the findings.</p>","PeriodicalId":10406,"journal":{"name":"Clinical Pharmacology : Advances and Applications","volume":"17 ","pages":"85-96"},"PeriodicalIF":3.1,"publicationDate":"2025-05-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12085126/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144092024","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Case Report of Sustained Cytokine Release Syndrome Due to Glofitamab and Literature Review.","authors":"Jingyi Yang, Qian Shen, Xiaoyan Ke, Wei Liu, Ping Yang","doi":"10.2147/CPAA.S515122","DOIUrl":"https://doi.org/10.2147/CPAA.S515122","url":null,"abstract":"<p><p>Glofitamab is a novel bispecific antibody targeting CD20×CD3, capable of simultaneously targeting CD20 and CD3 to activate T cells and release cytotoxic proteins that kill cancer cells. Cytokine release syndrome (CRS) is one of the most common adverse events observed in clinical trials of glofitamab. In most cases, CRS is mild, transient, and manageable with appropriate treatment. This paper reports a case of persistent CRS in a patient with mantle cell lymphoma following glofitamab treatment and reviews the relevant literature for reference.</p>","PeriodicalId":10406,"journal":{"name":"Clinical Pharmacology : Advances and Applications","volume":"17 ","pages":"79-83"},"PeriodicalIF":3.1,"publicationDate":"2025-04-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12049670/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143977150","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Parametric Population Pharmacokinetics Model Repository of Rifampicin: Model-Informed Individualized Therapy.","authors":"Gehang Ju, Xin Liu, Meng Gu, Lulu Chen, Xintong Wang, Chao Li, Nan Yang, Gufen Zhang, Chenchen Zhang, Xiao Zhu, Qingfeng He, Dongsheng Ouyang","doi":"10.2147/CPAA.S502272","DOIUrl":"https://doi.org/10.2147/CPAA.S502272","url":null,"abstract":"<p><strong>Introduction: </strong>Rifampicin is a crucial first-line anti-tuberculosis drug that has been extensively studied through population pharmacokinetic (popPK) analyses. This study aims to construct a comprehensive rifampicin popPK model repository to support model-informed individualized therapy.</p><p><strong>Methods: </strong>A systematic review was conducted using PubMed, Web of Science, and Embase databases up to September 2023 to retrieve popPK model articles on rifampicin. Extracted data included basic information, dosing regimens, sampling strategies, model parameters, and covariate details. Non-English studies, non-parametric models, and duplicates were excluded. The repository was built using R package mrgsolve, and a Shiny application was developed for simulation and individualized dosing predictions.</p><p><strong>Results: </strong>A total of 29 studies were included in the rifampicin model repository: 23 on adults, 5 on pediatrics, 1 on both populations, and 1 on pregnant women. Most rifampicin popPK models were one-compartment linear elimination models, with transit compartment or lagged absorption models improving drug absorption fitting. An allometric growth model based on fat-free mass (FFM) might improved model fit. Postmenstrual age (PMA) significantly impacted elimination in pediatric patients. All models underwent internal validation, with three studies validated externally. Significant variations in exposure predictions were observed among models, indicating challenges in achieving therapeutic targets under standard treatment.</p><p><strong>Discussion: </strong>The model repository provides a comprehensive resource for exploring various models and their application in different populations, supporting individualized rifampicin therapy. Further research is needed for special populations and to determine whether weight or FFM is more rational for dosing. External validation is essential for model development.</p>","PeriodicalId":10406,"journal":{"name":"Clinical Pharmacology : Advances and Applications","volume":"17 ","pages":"49-78"},"PeriodicalIF":3.1,"publicationDate":"2025-04-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12009037/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143968733","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Current Developments in Malaria Vaccination: A Concise Review on Implementation, Challenges, and Future Directions.","authors":"Malik Sallam, Arwa Omar Al-Khatib, Kholoud Sultan Al-Mahzoum, Doaa H Abdelaziz, Mohammed Sallam","doi":"10.2147/CPAA.S513282","DOIUrl":"10.2147/CPAA.S513282","url":null,"abstract":"<p><strong>Introduction: </strong>Malaria remains a persistent challenge in global health, disproportionately affecting populations in endemic regions (eg, sub-Saharan Africa). Despite decades of international collaborative efforts, malaria continues to claim hundreds of thousands of lives each year, with young children and pregnant women enduring the heaviest burden. This concise review aimed to provide an up-to-date assessment of malaria vaccines progress, challenges, and future directions.</p><p><strong>Methods: </strong>A PubMed/MEDLINE search (2015-2024) was conducted to identify studies on malaria vaccine development, implementation barriers, efficacy, and vaccination hesitancy. Clinical trials, reviews, and global health reports were included based on relevance to the review aims. No strict inclusion criteria were applied, and selection was guided by key review themes and policy relevance.</p><p><strong>Results: </strong>The introduction of pre-erythrocytic malaria vaccines (RTS,S/AS01 and R21/Matrix-M), represents an important milestone in malaria control efforts with promising results from the erythrocytic vaccine RH5.1/Matrix-M in recent clinical trials. However, the approval of these vaccines is accompanied by significant challenges such as the limited efficacy, the complexity of multi-dose regimens, and numerous barriers to widespread implementation in resource-limited settings. The review identified the complex challenges to broad malaria vaccination coverage, including logistical barriers, healthcare infrastructure effect, financial limitations, malaria vaccine hesitancy, among other obstacles in malaria-endemic regions. Promising developments in malaria vaccination, such as next-generation candidates (eg, mRNA-based vaccines), hold the potential to offer improved efficacy, longer-lasting protection, and greater scalability. There is a critical need to integrate malaria vaccination efforts with established malaria control interventions (eg, insecticide-treated bed nets, vector control strategies, and anti-malarial drugs).</p><p><strong>Conclusion: </strong>Achieving sustained control of malaria morbidity and mortality will require strong global collaboration, sufficient funding, and continuous efforts to address inequities in access and delivery of malaria control measures including the malaria vaccines.</p>","PeriodicalId":10406,"journal":{"name":"Clinical Pharmacology : Advances and Applications","volume":"17 ","pages":"29-47"},"PeriodicalIF":3.1,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11971972/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143794745","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Hypersensitivity Reaction After Administration of Crotalidae Polyvalent Immune Fab (CroFab).","authors":"Lena Truong, Takla R Anis, Layla Najibfard, Edwin Peck","doi":"10.2147/CPAA.S512508","DOIUrl":"https://doi.org/10.2147/CPAA.S512508","url":null,"abstract":"<p><p>Crotalidae polyvalent immune Fab (CroFab) is an antivenin that is FDA approved and commonly used to treat envenomations caused by North American pit vipers. Although CroFab has been widely used since the early 2000s, hypersensitivity reactions like type I, type IV, and angioedema have been reported in the literature. We present a case of CroFab induced hypersensitivity reaction in a 41-year-old male shortly after starting CroFab infusion. Furthermore, this patient developed anaphylaxis symptoms including: difficulty breathing, oropharyngeal edema, dysphagia, wheezing, and chest tightness. This was resolved upon stopping CroFab infusion and administering epinephrine, methylprednisolone, diphenhydramine, and famotidine. The reaction occurred again when CroFab was re-introduced despite infusing it at a much slower rate. Interestingly, this patient successfully tolerated crotalidae immune F(ab')2 (equine) antivenom (ANAVIP) upon switching him from CroFab. Hypersensitivity reactions to CroFab can be life-threatening and warrant immediate attention and treatment in a multidisciplinary setting.</p>","PeriodicalId":10406,"journal":{"name":"Clinical Pharmacology : Advances and Applications","volume":"17 ","pages":"25-28"},"PeriodicalIF":3.1,"publicationDate":"2025-03-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11910029/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143647530","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Therapeutic Effects of Curcumin on Oral Disease: A Systematic Review.","authors":"Novi Indriyani, Nanan Nur'aeny","doi":"10.2147/CPAA.S506396","DOIUrl":"10.2147/CPAA.S506396","url":null,"abstract":"<p><strong>Introduction: </strong>Curcumin is an extract from herbal plants that has been implicated in the treatment of any disease, including oral disease. There are various types of curcumin formulation as the option of the therapy. The aim of this review is to describe the curcumin mechanism in reducing the severity, pain score, and oral lesion size as the therapeutic effects.</p><p><strong>Methods: </strong>This systematic review used the Preferred Reporting Items for Systematic Review and Meta Analysis (PRISMA) guidelines. Databases used for articles include PubMed, Science Direct, and Scopus with inclusion criteria published from 2014 to 2024, full text, in English, and randomized controlled trial (RCT).</p><p><strong>Results: </strong>The present study included 21 RCTs with a total of 1244 individuals. In this study, curcumin was most commonly used for oral submucous fibrosis, with 9 studies demonstrating that curcumin has anti-inflammatory properties and inhibits collagenase. All studies demonstrate that curcumin produces significant results in the management of oral disease. The remain studies showed curcumin has antioxidant, inhibit collagenase, antifungal, and wound healing properties for oral leukoplakia, recurrent aphthous stomatitis (RAS), oral lichen planus (OLP), and denture stomatitis.</p><p><strong>Conclusion: </strong>Curcumin has anti inflammatory, antioxidant, inhibit collagenase, antifungal, and wound healing properties for reducing the severity of lesion, pain score and oral lesion size as the therapeutic effects in the patients with oral disease including OSMF, mucositis, leukoplakia, RAS, OLP, and denture stomatitis.</p>","PeriodicalId":10406,"journal":{"name":"Clinical Pharmacology : Advances and Applications","volume":"17 ","pages":"13-24"},"PeriodicalIF":3.1,"publicationDate":"2025-02-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11874755/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143540452","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}